98 results about "Cytokine storm" patented technology

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention belongs to the technical field of medicines, and discloses application of baicalein in drugs related to the treatment effect of S protein and LPS induced acute lung injury. Specifically, the invention discloses an application of baicalein in preparation of drugs playing a protective role in treating pulmonary edema, inflammatory cell infiltration and cytokine storm caused by acute lung injury induced by S protein combined with LPS. Pharmacological experiments prove that baicalein has an anti-inflammatory effect in treatment of acute lung injury induced by S protein combined with LPS, and can improve pulmonary edema and promote lesion lung tissue repair.

The invention provides a dynamic regulation and control method for optimizing CAR-T cell amplification conditions, which comprises the following steps: acquiring high-frequency cell activity monitoring data from a cell culture system, and extracting metabolic marker fluctuation and proliferation rate mutation from the high-frequency cell activity monitoring data to obtain real-time cell state parameters; comparing the real-time cell state parameters with a T cell subset proportion and a cell factor release mode in historical immune data of the patient to obtain a cell state deviation value, and determining an abnormal fluctuation condition of proliferation rate mutation according to the cell state deviation value; if the abnormal fluctuation of the proliferation rate mutation exceeds a preset fluctuation threshold value, capturing proliferation signal abnormity by analyzing metabolic marker fluctuation and metabolic waste accumulation according to the cell state deviation value; according to the targeted culture parameter set, adjusting the oxygen supply quantity and the culture solution microenvironment of an oxygen concentration control system to obtain a culture environment for inhibiting cytokine storm and proliferation signal abnormity.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The current invention provides novel approaches to the treatment of various disease states that lead to altered cytokine release or cytokine storms. These diseases include viral infections immunological and other non-immunological diseases. Specifically, the invention provides methods targeting ZHX2 including methods of inhibition, blocking or depletion of ZHX2 in order to treat various disease states.

The invention relates to the technical field of biological medicines, and particularly discloses application of betaine in preparation of a medicine for preventing or treating sepsis myocardial injury. Betaine (BET) provided by the invention can be used for effectively relieving cytokine storm caused by sepsis injury and inhibiting reduction of core body temperature of a mouse; the abnormal blood routine and blood biochemical indexes are improved. In addition, betaine can reduce generation of active oxygen in myocardial cells of the HL-1 mouse and improve mitochondrial membrane potential imbalance of the myocardial cells of the HL-1 mouse. The chemical structural formula of the betaine is shown in the specification.

Provided are compounds, compositions, and methods for re-polarizing tumor-associated macrophages (TAMs), reducing macrophage-mediated inflammation, and treating diseases. The compound or pharmaceutical composition can be administered to a subject in need thereof, the compound comprising a polymeric carbohydrate backbone and one or more mannose-binding C-type lectin receptor targeting moieties, and the therapeutic agent comprising one or more reactive hydroxyl groups and being attached to the polymeric carbohydrate backbone via a cleavable linker. The cleavable linker can comprise one or more carbonate and / or disulfide moieties. Diseases to be treated can include cancer, autoimmune diseases, inflammatory disorders, non-alcoholic steatohepatitis (NASH), acute respiratory distress syndrome (ARDS), sepsis, coronavirus infection, influenza infection, cytokine storm, and other macrophage-related diseases.

The present invention discloses a recombinant nucleic acid molecule encoded by at least ORF (100, 100a) to reduce cytokine storm during immunotherapy. The recombinant nucleic acid molecule comprises at least one first hairpin ring structure, at least one second hairpin ring structure and a first promoter (120). The first hairpin loop structure is formed from one or more first short hairpin RNA (130a) sequences. The first hairpin ring structure modulates the amount of interleukin 6 (IL6) cytokine during immunotherapy. The second hairpin loop structure is formed from one or more second short hairpin RNA (130b) sequences. The second hairpin ring structure modulates the amount of granulocyte monocyte colony stimulating factor (GMCSF) cytokine during immunotherapy and is disposed upstream or downstream of the first hairpin ring structure. The first promoter (120) is disposed upstream of the first hairpin ring structure and the second hairpin ring structure.

The present disclosure provides use of a promyelocytic leukemia 1 (PML-1) protein in preparation of a drug for inhibiting a cytokine storm, and belongs to the technical field of biomedicine. The present disclosure further provides use of a PML-1 protein and / or a product expressing the PML-1 protein in preparation of a drug for inhibiting a cytokine storm. In the present disclosure, the PML-1 protein and / or the product expressing the PML-1 protein can significantly inhibit the expression of proteins TAB1, TAK1, and p-TAK1 and inhibit inflammatory cytokines TNF-α, IL-1β, MIP-1α, IL-6, IL-8, and MCP-1 in an inflammatory signaling pathway, thereby inhibiting the cytokine storm. The PML-1 protein can be directly used for the treatment of inflammations and related diseases. Compared with traditional chemical anti-inflammatory drugs, the protein shows more significant curative effect, stronger specificity, lower toxicity, smaller side effects, and clearer biological functions, exhibiting broad application prospects.

An embodiment provides a method for treating a body fluid of a patient with an inflammatory cytokine storm, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

To provide methods for providing information on the specific types of bacteria among the bacteria contained in the intestinal flora to use them as materials for judging treatment policies and the like; and to provide methods for predicting COVID-19 exacerbation and methods for predicting cytokine storm exacerbation using the information.SOLUTION: Provided is a method for providing information on the genus Collinsella in the intestinal flora, comprising: an analysis step of analyzing the type and amount of the bacteria contained in a stool sample, and an information provision step of providing information on the ratio of the genus Collinsella in the intestinal flora, COVID-19 exacerbation being predicted based on the information provided.SELECTED DRAWING: None

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

We describe peptides and their uses for the treatment of, e.g. acute myocardial infarction and other cytokine storm-associated conditions.

The invention relates to a bispecific antibody targeting B7H7 and CD3 and application of the bispecific antibody. Wherein the bispecific antibody comprises: a first antigen binding region, the first antigen binding region having CD3 binding activity; and a second antigen binding region, the second antigen binding region having B7H7 binding activity; wherein the first antigen binding region comprises an anti-CD3 antibody, the anti-CD3 antibody comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises an amino acid sequence selected from at least one of SEQ ID NO: 4-6 and 66; the second antigen binding region comprises an anti-B7H7 antibody, the anti-B7H7 antibody comprises a heavy chain complementarity determining region HCDR, and the HCDR of the anti-B7H7 antibody comprises an amino acid sequence selected from at least one of SEQ ID NO: 26-28. The bispecific antibody with the sequence can be combined with human and monkey B7H7 with high specificity and high affinity, can be combined with human and monkey CD3 with low affinity and high specificity, can promote PBMC to kill tumor cells, and has good anti-cancer activity and higher treatment safety; the occurrence risk of cytokine storm caused by the CD3 bispecific antibody is effectively reduced.

The application provides a Brucella virus-influenza virus A co-infection mouse model and a construction method and application thereof, and belongs to the technical field of mouse model construction.The construction method of the Brucella virus-influenza virus A co-infection mouse model provided by the application is that after the mouse is anesthetized, the mouse is infected with the influenza virus A by using a lung delivery method, and 10-14 hours later, the mouse is infected with the Brucella by using the lung delivery method.The Brucella virus-influenza virus A co-infection mouse model is constructed, which is used for exploring the synergistic pathogenic mechanism of Brucella and influenza virus co-infection leading to acute lung injury and cytokine storm, screening characteristic indexes of co-infection acute lung injury and cytokine storm, and providing candidate targets for early diagnosis, prevention and clinical intervention treatment.

The invention provides a chimeric autoantibody receptor of a targeted acetylcholine receptor antibody, a CAAR-T cell and application of the chimeric autoantibody receptor in a medicine for preventing and treating myasthenia gravis, and belongs to the technical field of biological medicines. The invention provides a chimeric autoantibody receptor (CAAR) targeting an acetylcholine receptor antibody, which is characterized in that three extracellular domains of an AChR alpha subunit are connected in series through L1 and L2 connecting peptides or G4S connecting peptides to form an extracellular domain, and meanwhile, CD3 gamma only containing an ITAM motif is used as a signal transduction domain. The CAAR is expressed on the surface of a T cell, and the obtained CAAR-T not only has relatively strong binding capacity with an anti-AChR antibody, shows a relatively strong killing effect on pathogenic B cells expressing the anti-AChR antibody, can effectively relieve the symptom of myasthenia gravis, but also has relatively low risk of inducing cytokine storm, and has good drug safety.

The invention belongs to the field of medicine, and particularly relates to a nanoparticle HA-ADH-GL for inhibiting influenza virus as well as a preparation method and application of the nanoparticle HA-ADH-GL. The nanoparticle is a HA-ADH-GL conjugate synthesized by connecting glycyrrhizic acid (GL) with hyaluronic acid (HA) and a linker adipic dihydrazide (ADH), wherein the hyaluronic acid (HA) and the linker are good in biocompatibility and hydrophilicity. The nanoparticles can inhibit influenza virus replication and cytokine storm. The preparation method of the nanoparticles is simple, the cost is low, the water solubility of glycyrrhizic acid is improved, no biological safety risk and other problems exist, and reference is provided for research and development of antiviral drugs in the future.

The present invention discloses a recombinant nucleic acid molecule encoded by at least ORFs (100, 100a, 100b) for reducing cytokine storm during immunotherapy. The recombinant nucleic acid molecule comprises at least one hairpin loop structure and a first promoter (120). The hairpin loop structure regulates the amount of granulocyte-monocyte colony-stimulating factor (GMCSF) cytokine during immunotherapy. The hairpin loop structure is formed by one or more short hairpin RNA (130) sequences. The first promoter (120) is located upstream of the at least one hairpin loop structure.

The invention provides a chip model for detecting whether candidate drugs can cause cytokine storm, and belongs to the technical field of biomedicine. The chip model comprises a culture plate, the culture plate comprises a plurality of culture units, and each culture unit comprises a culture solution channel and a plurality of cell growth holes communicated with the culture solution channel; the bottom of the cell growth hole is lower than the bottom of the culture solution channel to form a growth hole concave part. According to the chip model, medicine combined immune cell killing can be carried out while 3D cell culture is realized, and whether side reaction is generated or not is detected in subsequent experiments. According to the application, higher-throughput culture and detection can be carried out, the experimental purpose of detecting and evaluating a plurality of anti-tumor drugs on the same chip is achieved, and drug safety evaluation can be carried out through components of a culture solution while drug effect evaluation is carried out.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure and a first promoter. The at least one hairpin loop structure is formed by one or more short hairpin RNA sequences. The at least one hairpin loop structure regulates an amount of Interleukin 6 (IL6) cytokine during immunotherapy. The first promoter is disposed upstream of the at least one hairpin loop structure.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to a chimeric antigen receptor targeting MUC16 and application of the chimeric antigen receptor in tumor treatment. Specifically, aiming at MUC16 molecules, a single-chain antibody with high affinity is successfully prepared, on the basis of high-affinity scFv, a CAR carrier and CAR-NK cells for recognizing MUC16 are constructed, PD1 of the CAR-NK cells is further knocked out through a CRISPR / Cas9 system, immune cell depletion is reduced, and then the purpose of synergistically and effectively treating tumors is achieved. According to the invention, severe cytokine storm, neurotoxicity or graft versus host disease can be avoided, the side effect is small, and immune escape can be prevented. Moreover, the NK92 cell line can be amplified and passaged infinitely, and the cost is lower, so that the NK92 cell line is more suitable for treating solid tumors, and has a good practical application value.

The invention discloses a veterinary epidemic prevention medicine as well as a preparation method and application thereof, and relates to the field of veterinary drug research and development and veterinary medicine, and the veterinary epidemic prevention medicine is prepared from the following components in parts by volume: 9.0-9.8 parts of Shuanghuanglian; 0.2 to 1.0 part of polyinosinic cell; through the molecular chaperone effect of the Shuanghuanglian and the polyinosinic-polycytidylic acid, the permeability and retention of the antiviral drug in myocardial tissues are remarkably improved, the technical bottleneck that a traditional drug is insufficient in myocardial virus load control is broken through, the damage of cytokine storm to myocardial cells is effectively inhibited while the antiviral immune response is enhanced, and the curative effect is good. The ratio of the Shuanghuanglian to the polyinosinic acid is optimized, the basic antiviral activity of the Shuanghuanglian is guaranteed, the immune regulation function of the polyinosinic acid is exerted with the minimum effective dose, the dose-dependent side effect is avoided, the medication process is simplified in clinical application, an innovative medicine combination with high efficiency, safety and economical efficiency is provided for the modern breeding industry, and the clinical application prospect is wide. And the method has remarkable industrial popularization value.

The present invention discloses a recombinant nucleic acid molecule encoded by at least ORFs (100, 100a) for reducing cytokine storm during immunotherapy. The recombinant nucleic acid molecule comprises at least one hairpin loop structure and a first promoter (120). The at least one hairpin loop structure is formed by one or more short hairpin RNA (130) sequences. The at least one hairpin loop structure regulates the amount of interleukin 6 (IL6) cytokine during immunotherapy. The first promoter (120) is located upstream of the at least one hairpin loop structure.

The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating compounds. The methods can involve administering CALD-treating compounds to a patient suffering from CALD or cytokine storm.

The invention provides an application of an IDO1 inhibitor as a sepsis therapeutic agent, and particularly provides an application of the IDO1 inhibitor for preparing a pharmaceutical composition for treating sepsis, and in the invention, the IDO1 inhibitor can effectively improve cytokine storm and immunosuppression of sepsis. In addition, the IDO1 inhibitor can improve the survival rate of sepsis mice in an immunosuppression state when the mice are subjected to secondary infection. And a new insight is provided for the treatment of sepsis.

This invention relates to the field of biomedicine, specifically to the combined application of interferon-alpha (IFN-α) and NF-κB signaling pathway inhibitors, particularly the application of interferon-alpha combined with bortezomib in the preparation of drugs for the prevention and / or treatment of viral infections. Host-produced lactate is a key microenvironmental factor driving the shift of IFN-α from "anti-inflammatory" to "pro-inflammatory." Lactic acid, in conjunction with IFN-α, excessively activates the NF-κB signaling pathway, thereby triggering a cytokine storm. Based on this novel mechanism, this invention creatively proposes the combined use of IFN-α and bortezomib. This combination effectively blocks lactate / IFN-α-induced NF-κB overactivation, retaining the potent antiviral activity of IFN-α while completely reversing its side effect of exacerbating inflammation in the later stages of viral infection, achieving a dual effect of "antiviral" and "inflammatory control."

The present invention relates to compound of Formula 1 for use in treating IPF, by reducing collagen deposition in lungs, attenuating the fibrotic marker's expression (in IPF cell-lines Bleomycin induced rat lungs) and improving the bleomycin induced pathological changes in rat lungs, and ARDS, by reducing the cytokine storm. The invention also relates to compound of Formula 1 for use in treating various fibrotic disorders like lung injuries caused by virus or bacterial infections, cardiac, hepatic and kidney fibrosis.

A cancer neoantigen-expressing cell membrane GRP94-targeting chimeric antigen receptor, comprising a signal peptide region, a cell membrane GRP94-targeting antigen binding domain, a hinge region, a transmembrane domain, and a signal transduction activation domain which are connected in sequence from the amino terminus to the carboxyl terminus, wherein the nucleotide sequence and amino acid sequence of the signal peptide region are as shown in SEQ ID No: 1 and SEQ ID No: 2 respectively; and the antigen binding domain is a portion of an antibody itself that targets cancer neoantigen-expressing cell membrane GRP94, or formed between portions of the antibody itself or between a portion thereof and an antibody region for another target. A novel chimeric antigen receptor (CAR)-engineered NK immune cell and a cancer drug can rapidly induce apoptosis in novel cancer cells having potentially cancer antigen-expressing cell membrane GRP94 protein, generate no toxic and side effects such as cytokine storms, and have off-the-shelf universal applicability, thereby providing a new choice for cell immunotherapy for cancers and also laying a foundation for accurate individualized treatment for cancer treatment.

The invention belongs to the technical field of biology, and particularly relates to a micropeptide CIM53 as well as a coding gene and application thereof. The amino acid sequence of the micropeptide CIM53 is as shown in SEQ ID NO. 1, and the nucleotide sequence of the gene for coding the micropeptide CIM53 is as shown in SEQ ID NO. 2. According to the invention, it is found for the first time that cell overexpression of CIM53 can down-regulate various cytokines induced by Poly (I: C), IFN-beta and LPS; the CIM53 remarkably improves the survival rate of C57BL / 6J mice treated by LPS, relieves LPS-induced lung injury of the mice, and plays an important role in preparation of drugs for treating cytokine storm-related diseases; the CIM53 can obviously improve lung injury of mice infected by the H1N1 influenza virus, can obviously improve the survival rate of the mice when being used together with OSV medicines, and has an important effect on preparation of medicines for treating diseases related to virus-induced cytokine storm.

The invention belongs to the technical field of medicines, and particularly relates to application of traditional Chinese medicine active ingredients in antianaphylaxis, in particular to application of rare ginsenoside Rh1 in preparation of medicines for preventing or treating anaphylaxis. According to the invention, the action mechanism of Rh1 in resisting anaphylaxis is systematically clarified by integrating network pharmacology, molecular docking, molecular dynamics simulation and transcriptomics technologies for the first time. The Rh1 acts on four key host targets, namely ALB, CASP3, NFKB1 and STAT3 at the same time, regulates and controls an MAPK signal channel, a Th17cell diffusion channel and a PI3K-Akt signal channel, and synergistically exerts the dual effects of inhibiting allergens from invading host cells and relieving cytokine storm. The Rh1 and the four key targets all have high affinity binding. The invention provides a brand new theoretical basis and a clear mechanism support for developing Rh1-based broad-spectrum, high-efficiency and low-toxicity anti-anaphylaxis drugs.